I know enough financially broke startups to confirm that a working prototype is only a small part of a successful business.
The approach to intellectual property in China is much more open, partly because the leaders understand that technical expertise is more than just a one-off design, and competitors probably can't enter the market without significant capital investment and risk. In the case of healthcare, I suspect that regulators will prevent any vaccines manufactured with sub-standard procedures, such as those made in university labs.
The approach to intellectual property in China is much more open, partly because the leaders understand that technical expertise is more than just a one-off design, and competitors probably can't enter the market without significant capital investment and risk. In the case of healthcare, I suspect that regulators will prevent any vaccines manufactured with sub-standard procedures, such as those made in university labs.